

Contents

List of Contributors	<i>XIX</i>
Preface	<i>XXV</i>
A Personal Foreword	<i>XXVII</i>

Part I

1	Process Logistics, Testing Strategies and Automation Aspects	3
	<i>Hansjoerg Haas, Robert S. DeWitte, Robert Dunn-Dufault, and Andreas Stelzer</i>	
1.1	Introduction	3
1.2	The Process from Raw Ingredients to Data	3
1.2.1	Compound Management	5
1.2.2	Cell Biology	6
1.2.3	Lead Profiling	7
1.2.4	Liquid Chromatography/Mass Spectrometry	7
1.3	DMPK Testing Strategies: the Process from Data to Decisions	8
1.4	New Questions, New Assays and New Technologies Challenge the Process	10
1.5	Organizational Models to Scale Up the Process	11
1.5.1	Food Court	11
1.5.1.1	The Fast Food Restaurant	12
1.5.1.2	The Family Restaurant Chain	12
1.6	Critical Factors to Improve the Process	13
1.7	Materials in ADME/Tox Screening	14
1.8	Machines and Equipment in ADME/Tox Screening	17
1.8.1	Liquid Handlers	17
1.8.2	Detection and Analysis	17
1.9	Software, Data Retrieval, Analysis, Manipulation and Interpretation	18
1.10	Environment and Management = Organizational Structure in ADME/Tox Screening	19

1.11	Methods in ADME/Tox Screening	20
1.11.1	Examples of Whole-Process Approaches	20
1.11.1.1	Automation Islands with Manual Data Upload to a LIMS System	21
1.11.1.2	Complete Physical Integration and Automation	21
1.11.1.3	Federated Physical Automation with Software Integration	22
1.12	Conclusions	22
	References	23
2	Prediction of Drug-Likeness and its Integration into the Drug Discovery Process	25
	<i>Ansgar Schuffenhauer and Meir Glick</i>	
2.1	Introduction	25
2.2	Computational Prediction of Drug-Likeness	26
2.2.1	Machine Learning	26
2.2.2	Empirical Rules and Their Basis	30
2.2.3	Drug-Likeness of Natural Products	32
2.2.4	Do Ligands of Different Target Classes Differ in Their Drug-Like Properties?	34
2.2.5	Unwanted Structural Elements	34
2.3	What is the Best Practice in Utilizing Drug-Likeness in Drug Discovery?	35
2.4	Concluding Discussions	37
	References	38
3	Integrative Risk Assessment	41
	<i>Bernard Faller and Laszlo Urban</i>	
3.1	The Target Compound Profile	41
3.1.1	Introduction	41
3.1.2	The Importance of the Projected Clinical Compound Profile in Early Drug Discovery	42
3.1.3	The Impact of Delivery On the Design of the Drug Discovery Process	43
3.2	The Concept of Hierarchical Testing in Primary and Follow-Up Assays	45
3.2.1	Impact of Turn-Around Time	47
3.2.2	Assay Validation and Reference Compounds	47
3.2.3	Requirements of Profiling Assay Quality	48
3.2.4	The Importance of Follow-Up Assays	48
3.3	Exposure Assays	49
3.3.1	Basic Absorption Assays	49
3.3.1.1	Solubility Assays	50
3.3.1.2	Permeability Assays	50
3.3.2	Active Transports and Efflux	51
3.3.3	Metabolism	51
3.3.4	Distribution and Elimination	51
3.3.5	Drug–Drug Interactions	53

- 3.3.6 *in vivo* Correlations 53
- 3.4 Iterative Assays: Link Between Assays 54
- 3.5 Specific Safety Profiling Assays 56
- 3.5.1 Sensitivity and Specificity of Safety Assays should be Adjusted to the Phase of Drug Discovery 58
- 3.5.2 Addressing Species Specificity in Early *In Vitro* Assays 58
- 3.6 Data Reporting and Data Mining 59
- 3.6.1 Decision Making: Trend Analysis, Go/No Go Decisions 60
- 3.7 Integrative Risk Assessment 61
- References 64

Part II

- 4 Solubility and Aggregation 71**
William H. Streng
 - 4.1 Importance of Solubility 71
 - 4.2 Factors Influencing Solubility 72
 - 4.3 Methods Used to Determine Solubility 74
 - 4.4 Approaches to Solubility 76
 - 4.5 Solubility in Non-Aqueous Solvents and Co-Solvents 78
 - 4.6 Solubility as a Function of pH 79
 - 4.7 Effect of Aggregation Upon Solubility 83
 - 4.8 Dependence of Dissolution upon Solubility 86
 - 4.9 Partitioning and the Effect of Aggregation 87
 - 4.10 Solubility in Simulated Biological Fluids 89
 - References 90

- 5 *In Silico* Tools and *In Vitro* HTS Approaches to Determine Lipophilicity During the Drug Discovery Process 91**
Sophie Martel, Vincent Gasparik, and Pierre-Alain Carrupt
 - 5.1 Introduction 91
 - 5.2 Virtual Filtering: *In Silico* Prediction of log P and log D 92
 - 5.2.1 Lipophilicity of Neutral Substances: *In Silico* Methods to Predict log P_{oct}^N 92
 - 5.2.1.1 2D Fragmental Approaches 92
 - 5.2.1.2 Prediction Methods Based on 3-D Molecular Structure 95
 - 5.2.1.3 General Comments on the Prediction of log P_{oct} 96
 - 5.2.2 Prediction Models for log P in Other Solvent/Water Systems of Neutral Compounds 97
 - 5.2.3 Prediction Models for log P of Ionic Species (log P^I) 97
 - 5.3 Experimental Filtering: the ADMET Characterization of a Hit Collection 98
 - 5.3.1 HTS log P/log D Determination Based on Microtiterplate Format 98
 - 5.3.2 Chromatographic Methods 100

- 5.3.2.1 Reverse-Phase Liquid Chromatography 100
- 5.3.2.2 Immobilized Artificial Membranes 102
- 5.3.2.3 Hydrophilic Interaction Chromatography 103
- 5.3.2.4 Capillary Electrophoresis 104
- 5.3.3 A Global View On *In Vitro* HTS Methods to Measure $\log P/\log D$ 104
- 5.4 Concluding Remarks: Efficacy or Accuracy Dilemma 105
- References 107

6 Membrane Permeability – Measurement and Prediction in Drug Discovery 117

Kiyohiko Sugano, Lourdes Cucurull-Sanchez, and Joanne Bennett

- 6.1 Overview of Membrane Permeation 117
 - 6.1.1 Structure, Physiology and Chemistry of the Membrane 117
 - 6.1.2 Passive Transcellular Pathway: pH Partition Theory as the Basis of Understanding Membrane Permeability 118
 - 6.1.3 Paracellular Pathway 119
 - 6.1.4 Active Transporters 119
 - 6.1.5 *In Vitro*–*In Vivo* Extrapolation 119
- 6.2 *In Vitro* Cell Models 121
 - 6.2.1 Intestinal Cell Culture Models 121
 - 6.2.2 BBB Cell Culture Models 122
 - 6.2.3 Cell Models to Study Active Transporters 123
 - 6.2.4 Correlation of *in Vitro* Models to Human P_{eff} and Fraction Absorbed Data 124
 - 6.2.5 Correlation of Cell Culture Models with *In Vivo* Brain Penetration 124
- 6.3 Artificial Membranes 125
 - 6.3.1 Partition and Permeation 125
 - 6.3.2 Parallel Artificial Membrane Permeation Assay: Recent Progress 126
 - 6.3.2.1 Understanding PAMPA 126
 - 6.3.2.2 Variation of PAMPA: Recent Progress 127
 - 6.3.2.3 Phospholipid Vesicle PAMPA 127
 - 6.3.2.4 Phospholipid–Octanol PAMPA 127
 - 6.3.2.5 Tri-Layer PAMPA 127
 - 6.3.2.6 Mucus Layer Adhered PAMPA 127
 - 6.3.3 Application of PAMPA for Drug Discovery 128
- 6.4 Limitation of *In Vitro* Assays 128
 - 6.4.1 Impact of UWL on Permeability 128
 - 6.4.2 Membrane Binding 129
 - 6.4.3 Low Solubility 129
 - 6.4.4 Difference of the Paracellular Pathway 129
 - 6.4.5 Interlaboratory Variability 129
- 6.5 Computational Approaches/*In Silico* Modeling 130

6.5.1	<i>In Vivo</i> Systems	130
6.5.2	<i>In Vitro</i> Cellular Membrane Systems	132
6.5.3	Artificial Membranes	134
6.5.4	Perspectives	135
6.6	Outlook	135
	References	136
7	Drug Metabolism and Reactive Metabolites	145
	<i>Alan P. Watt</i>	
7.1	Introduction to Drug Metabolism	145
7.1.1	Historical Perspective	145
7.1.2	<i>In Vitro</i> Metabolism	146
7.1.3	Cytochrome P450	148
7.1.4	Prediction of Drug Metabolism	149
7.2	Adverse Drug Reactions	149
7.2.1	ADR Classification	150
7.2.2	Idiosyncratic Drug Reactions	150
7.3	Bioactivation	151
7.3.1	Definition	151
7.3.2	Reactions of Electrophilic Metabolites	151
7.3.3	Glutathione	151
7.3.4	Detection of GSH Conjugates	151
7.3.5	Acyl Glucuronides	152
7.3.6	Free Radicals and Oxidative Stress	152
7.4	Reactive Metabolites and Idiosyncratic Toxicity	153
7.4.1	The Hapten Hypothesis	153
7.4.1.1	Immune-Mediated Cutaneous Reactions	153
7.4.2	The Danger Hypothesis	153
7.4.3	Alternate Perspectives to Covalent Binding	154
7.4.3.1	Non-Toxicological Covalent Binding	154
7.4.3.2	Covalent Binding as Detoxification	154
7.5	Measurement of Reactive Metabolites	155
7.5.1	Trapping Assays	155
7.5.1.1	Soft Nucleophiles	155
7.5.1.2	Hard Nucleophiles	155
7.5.2	Mass Spectrometric Detection of GSH Conjugates and Mercapturic Acids	155
7.5.3	Radiometric Assays	156
7.5.3.1	Covalent Binding to Liver Microsomes	157
7.5.3.2	<i>Ex Vivo</i> Covalent Binding	157
7.5.3.3	¹⁴ C Cyanide Trapping	157
7.5.3.4	Radiolabeled Soft Nucleophile Trapping	158
7.5.4	Alternate Approaches	158
7.6	Strategies for Minimizing Reactive Metabolite Risk	159
7.6.1	Dose and Exposure	159

7.6.2	Structural Alerts	159
7.6.3	Cascade for Radiolabeled Covalent Binding Experiments	160
7.6.4	Criteria for Progression	160
7.7	Conclusions	160
	References	161

8 Drug–Drug Interactions: Screening for Liability and Assessment of Risk 165

Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim, and Michael Zientek

8.1	Introduction	165
8.2	<i>In Silico</i> Approaches	167
8.3	Perpetrators of Drug–Drug Interactions: Enzyme Inhibition	169
8.3.1	Competitive Inhibition	169
8.3.2	Conventional CYP Inhibition Screen	170
8.3.3	Fluorescent Inhibition Screen	172
8.3.4	DDI Single Point versus IC ₅₀ Determinations	172
8.3.5	DDI Cocktail Assay	173
8.3.6	Mechanism-Based Inhibition	174
8.4	Perpetrators of Drug–Drug Interactions: Enzyme Induction	176
8.4.1	Ligand Binding Assay	177
8.4.2	Reporter Gene (Transactivation) Assays	178
8.4.3	Overall Evaluation of High-Throughput Induction Assays	179
8.5	Drug–Drug Interactions; Victims of Interaction; Reaction Phenotyping	179
8.5.1	Chemical Inhibition	180
8.5.2	Recombinant Human CYP Enzymes	181
8.6	Predictions of Drug–Drug Interactions	182
8.6.1	New Compounds as Potential DDI Perpetrators	183
8.6.2	New Compounds as Potential DDI Victims	184
8.7	Summary	187
	References	188

9 Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery 197

Franco Lombardo, R. Scott Obach, and Nigel J. Waters

9.1	Introduction: Importance of Plasma Protein Binding	197
9.2	Impact of Plasma Protein Binding on PK, Exposure, Safety Margins, Potency Screens and Drug–Drug Interaction	197
9.3	Methodologies for Measuring Plasma Protein Binding	201
9.4	Physicochemical Determinants and <i>In Silico</i> Prediction of Plasma Protein Binding	206
9.5	Volume of Distribution: General Considerations and Applications to Experimental Pharmacokinetics and Drug Design	208
9.5.1	Prediction of Human Volume of Distribution	210

9.5.1.1	Prediction of Human Volume of Distribution from Animal Pharmacokinetic Data	210
9.5.1.2	Prediction of Human Volume of Distribution from <i>In Vitro</i> Data	212
9.5.1.3	Prediction of Human Volume of Distribution from <i>In Silico</i> Methods	213
9.6	Relationship Between Clearance, VDss and Plasma Protein Binding	213
9.7	Summary and Conclusions	214
	References	215
10	Putting It All Together	221
	<i>Pamela Berry, Neil Parrott, Micaela Reddy, Pascale David-Pierson, and Thierry Lavé</i>	
10.1	Challenges in Drug Discovery	221
10.2	Methodological Aspects	222
10.2.1	PBPK	222
10.2.2	PK/PD	225
10.3	Strategic Use of PBPK During Drug Discovery	226
10.4	Strategic Use of PK/PD During Drug Discovery	227
10.5	Application During Lead Identification	227
10.6	Application During Lead Optimization	232
10.7	Application During Clinical Lead Selection	235
10.8	Limitations with Current Methodology and Approaches	236
10.9	Conclusions	238
	References	238
Part III		
11	Genetic Toxicity: <i>In Vitro</i> Approaches for Hit and Lead Profiling	243
	<i>Richard M Walmsley and Nicholas Billinton</i>	
11.1	Introduction	243
11.2	Definitions	245
11.3	Major Challenges for Early, Predictive Genotoxicity Testing	246
11.4	Practical Issues for Genotoxicity Profiling: Vehicle, Dose, Dilution Range and Impurity	248
11.4.1	Vehicle and Dose	248
11.4.2	Dilution Range	249
11.4.3	Purity	249
11.5	Computational Approaches to Genotoxicity Assessment: " <i>In Silico</i> " Assessment	250
11.5.1	How Should <i>In Silico</i> Methods be Applied in Hit and Lead Profiling?	252
11.6	Genotoxicity Assays for Screening	253
11.6.1	Gene Mutation Assays	254

- 11.6.2 The Ames Test and Variants 255
- 11.6.3 Mammalian Cell Mutation Assays 256
- 11.6.4 *Saccharomyces cerevisiae* ("Yeast") Mutation Assays 256
- 11.7 Chromosome Damage and Aberration Assays 256
 - 11.7.1 Aberrations 256
 - 11.7.2 Micronuclei 257
 - 11.7.3 "Comet" Assay 258
 - 11.7.4 DNA Adduct Assessment 258
 - 11.7.5 Gene Expression Assays 259
 - 11.7.5.1 Prokaryotic 259
 - 11.7.5.2 Eukaryotic 259
- 11.8 Using Data from *In Vitro* Profiling: Confirmatory Tests, Follow-Up Tests, and the Link to Safety Assessment and *In Vivo* Models 260
 - 11.8.1 Annotations from Screening Data 261
 - 11.8.2 Annotations from Positive Screening Data 262
 - 11.8.2.1 Gene Mutation Assays 262
 - 11.8.2.2 Chromosome Damage Assays 262
 - 11.8.2.3 Reporter Assays 263
- 11.9 Can a Genetic Toxicity Profile Inform *In Vivo* Testing Strategies? 263
 - 11.9.1 Prospects for *In Vivo* Profiling of Hits and Leads for Genotoxicity 264
- 11.10 What to Test, When and How? 265
 - 11.10.1 Profiling Entire Libraries: >100 000 Compounds/Year 265
 - 11.10.2 Profiling Hits: 10 000–100 000 Compounds/Year 265
 - 11.10.3 Profiling in Lead Optimization: 2000–10 000 Compounds/Year 266
- 11.11 Summary 267
- References 267

12 ***In Vitro* Safety Pharmacology Profiling: an Important Tool to Decrease Attrition** 273

Jacques Hamon and Steven Whitebread

- 12.1 What is "*In Vitro* Safety Pharmacology Profiling?" 273
- 12.2 Examples of Drug Failures Due to Secondary Pharmacology 274
 - 12.2.1 Components 275
 - 12.2.1.1 Target Selection 275
 - 12.2.1.2 Target Annotation 276
 - 12.2.1.3 Examples of *In Vitro* Safety Pharmacology Profiling Panels 277
 - 12.3 Processes 280
 - 12.3.1 Assay Requirements and Technologies 280
 - 12.3.2 Binding and/or Functional Assays 284
 - 12.3.3 Processes and Logistics 286
- 12.4 Application to Drug Discovery 287
 - 12.4.1 How and When to Use *In Vitro* Safety Pharmacology Profiling 287
 - 12.4.2 Pharmacological Promiscuity and Its Clinical Interpretation 288
 - 12.4.3 Relevance of Potency and Therapeutic Index (TI) 290

12.4.4	Possible Benefits of Off-Target Effects	291
12.5	Conclusions and Outlook	291
	References	292
13	Knowledge-Based and Computational Approaches to <i>In Vitro</i> Safety Pharmacology	297
	<i>Josef Scheiber, Andreas Bender, Kamal Azzaoui, and Jeremy Jenkins</i>	
13.1	Introduction	297
13.1.1	The Value of Safety Pharmacology Data: the Value and Relevance of Complete, Standardized Data Matrices for <i>In Silico</i> Prediction of Adverse Events	298
13.2	“Meta Analysis” of Safety Pharmacology Data: Predicting Compound Promiscuity	304
13.2.1	Introduction	304
13.2.2	Data Analysis	305
13.2.2.1	Hit Rate Parameter and Chemical Profiling	305
13.2.2.2	Computational Efforts: Generation of Hypotheses	307
13.2.2.3	Promiscuity and Attrition Rate	308
13.2.2.4	Conclusion on Promiscuity Prediction	310
13.3	Prediction of Off-Target Effects of Molecules Based on Chemical Structure	310
13.3.1	Introduction	310
13.3.2	Available Databases and Desired Format	311
13.3.3	The Best Established Technologies for <i>In Silico</i> Target Fishing	313
13.3.3.1	Similarity Searching in Databases	313
13.3.3.2	Data Mining in Annotated Chemical Databases	314
13.3.3.3	Data Mining on Bioactivity Spectra	314
13.4	Future Directions	316
	References	317

Part IV

14	Discovery Toxicology Screening: Predictive, <i>In Vitro</i> Cytotoxicity	325
	<i>Peter J. O'Brien</i>	
14.1	Introduction	325
14.2	Basis of Need for Discovery Toxicology Screening	326
14.2.1	High Attrition at High Cost	326
14.2.2	High Proportion of Attrition Due to Adverse Safety	326
14.2.3	Discovery Screening Reduces Attrition by An Order of Magnitude	326
14.3	Obstacles to Discovery Toxicology Screening	327
14.4	Need to Coordinate Cytotoxicity Screening with Other Discovery Safety Assessments	327
14.5	Discovery Cytotoxicology	329
14.5.1	Biomarkers for Safety versus Efficacy for Screening	329

14.5.2	Past Failure of Cytotoxicity Assessments	329
14.5.2.1	Insufficient Exposure	329
14.5.2.2	Measurement of Cell Death	330
14.5.3	Effective Cell-Based Assays for Marked and Acute Cytotoxicity	331
14.5.4	Characteristics of an Optimally Effective Cell Model of Toxicity	331
14.5.4.1	Need for Morphological and Functional Parameters	333
14.5.4.2	Need for Multiple and Mechanistic Parameters	333
14.5.4.3	Need for Single-Cell Monitoring	333
14.5.4.4	Need for Effective Parameters	334
14.5.4.5	Need for Validation with Human Toxicity Data	336
14.6	High Effectiveness of an HCA Cell Model in Predictive Toxicology	337
14.6.1	Background on HCA	337
14.6.2	Idiosyncratic Hepatotoxicity	337
14.6.3	Characteristic Pattern and Sequence of Cytotoxic Changes	338
14.6.4	Safety Margin	338
14.6.5	Hormesis	338
14.6.6	Implementation of HCA Cytotoxicity Testing in Drug Discovery	339
14.6.7	Limitations of HCA Cytotoxicity Testing in Drug Discovery	340
14.7	Future Impact of Cytotoxicity Testing	340
	References	341

15 **Predicting Drug-Induced Hepatotoxicity: *In Vitro*, *In Silico* and *In Vivo* Approaches** 345

Jinghai J. Xu, Amit S. Kalgutkar, Yvonne Will, James Dykens, Elizabeth Tengstrand, and Frank Hsieh

15.1	Introduction	345
15.2	Reactive Metabolites	346
15.2.1	Assays and <i>In Silico</i> Knowledge to Assess Bioactivation Potential	347
15.2.1.1	<i>In Vitro</i> Reactive Metabolite Trapping Studies	347
15.2.1.2	Covalent Binding Determinations	348
15.2.2	Utility of Reactive Metabolite Trapping and Covalent Binding Studies in Drug Discovery	348
15.2.3	Are Reactive Metabolite Trapping and Covalent Binding Studies Reliable Predictors of Hepatotoxic Potential of Drug Candidates?	348
15.2.4	Mitigating Factors Against Hepatotoxicity Risks Due to Bioactivation – a Balanced Approach Towards Candidate Selection in Drug Discovery	351
15.2.5	Future Directions	355
15.3	Mitochondrial Toxicity	356
15.3.1	Uncouplers of Mitochondrial Respiration	358
15.3.2	Drugs that Inhibit OXPHOS Complexes	358
15.3.3	Drugs that Induce the Mitochondrial Permeability Transition Pore (MPT)	359
15.3.4	Drugs Inhibiting mtDNA Synthesis and Mitochondrial Protein Synthesis	359
15.3.5	Inhibition of Fatty Acid β -Oxidation or Depletion of CoA	360

15.3.6	<i>In Vitro</i> and <i>In Vivo</i> Assessment of Drug-Induced Mitochondrial Dysfunction	360
15.4	Oxidative Stress	363
15.4.1	Sources of Oxidative Stress	363
15.4.2	Measurements of Oxidative Stress	363
15.4.3	Critical Review: Is There Sufficient Clinical, Pre-Clinical and <i>In Vitro</i> Data to Substantiate the Link Between Oxidative Stress and Idiosyncratic Liver Injury?	364
15.5	Inhibition of Bile Salt Efflux Protein and Drug-Induced Cholestasis	365
15.5.1	<i>In Vitro</i> and <i>In Vivo</i> Assays to Measure BSEP Inhibition	365
15.5.2	Critical Review: Is There a Link between BSEP Inhibition, Drug-Induced Cholestasis and Idiosyncratic Liver Injury?	368
15.6	Biomarkers	369
15.6.1	Hepatocellular Injury	370
15.6.2	Cholestatic Injury	370
15.6.3	Application of Serum Chemistry Markers	370
15.6.4	Need for New Biomarkers	371
15.6.5	Biomarker Discovery Efforts	372
15.6.6	Approaches for Biomarker Discovery	372
15.6.6.1	Development of <i>In Vivo</i> Biomarkers	373
15.6.6.2	Development of <i>In Vitro</i> Biomarkers	373
15.6.6.3	Biomarker Validation	374
15.6.7	Future Biomarker Directions	374
15.7	Conclusions	375
	References	376
16	Should Cardiosafety be Ruled by hERG Inhibition?	
	Early Testing Scenarios and Integrated Risk Assessment	387
	<i>Dimitri Mikhailov, Martin Traebert, Qiang Lu, Steven Whitebread, and William Egan</i>	
16.1	Introduction	387
16.2	Role of Ion Channels in Heart Electrophysiology	389
16.3	hERG Profiling Assays	391
16.3.1	Cell-Free Competition Binding Assays	392
16.3.1.1	Radioligand Binding	393
16.3.1.2	Fluorescence Polarization	393
16.3.2	Non-Electrophysiological Functional Cellular Assays	393
16.3.2.1	Rubidium Efflux and Thallium Influx	393
16.3.2.2	Membrane Potential-Sensitive Fluorescent Dyes	394
16.3.3	Higher-Throughput Planar Patch Technologies	394
16.3.4	Non-hERG Ion Channel Assays Related to Cardiotoxicity	395
16.3.5	Nonclinical Cardiosafety Assays in Early Drug Development	396
16.4	Computational Models for hERG	398
16.4.1	Pharmacophore Models	398
16.4.2	Docking to Homology Models	399

16.4.3	QSAR Models	400
16.5	Integrated Risk Assessment	401
16.5.1	Cardiosafety Assessment of Early Discovery Projects	401
16.5.2	Cardiosafety Assessment of Preclinical Positive Signals	403
16.6	Summary	405
	References	406
17	Hematotoxicity: <i>In Vitro</i> and <i>Ex Vivo</i> Compound Profiling	415
	<i>David Brott and Francois Pognan</i>	
17.1	Introduction	415
17.2	Known Compounds with Hematotoxic Potential	417
17.3	Tiered Cascade of Testing	419
17.3.1	Tier 1 Tests	420
17.3.2	Tier 2 Tests	426
17.3.3	Tier 3 Tests	428
17.4	Triggers for Hematotoxicity Testing	430
17.5	Conclusions	433
	References	433
18	Profiling Adverse Immune Effects	439
	<i>Wim H. De Jong, Raymond Pieters, Kirsten A Baken, Rob J. Vandebriel, Jan-Willem Van Der Laan, and Henk Van Loveren</i>	
18.1	Immunotoxicology	439
18.1.1	The Immune System and Immunotoxicology	439
18.1.2	Detection of Immunotoxicity	442
18.1.3	Evaluation of the Immune System in Toxicity Studies	443
18.1.4	Testing for Induction of Allergy	445
18.1.5	Testing for Induction of Autoimmunity	446
18.1.5.1	Introduction	446
18.1.5.2	Assays for Testing the Induction of Autoimmunity	446
18.1.5.3	Alternative Approach for Evaluation of Autoimmunity Potential of Chemicals	447
18.1.6	Structures Associated with Immunotoxicity	449
18.1.7	Immunostimulation by Components of the Immune Systems Used as Therapeutics	450
18.2	Non-Animal Approaches for the Determination of Immunotoxicity	451
18.2.1	<i>In Silico</i> Approaches	451
18.2.2	<i>In Vitro</i> Approaches to Test Various Aspects of Immunotoxicity	451
18.2.2.1	Introduction	451
18.2.2.2	Immunosuppression	453
18.2.2.3	Chemical Sensitization	454
18.2.2.4	Conclusions	456
18.2.3	Toxicogenomics	456
18.2.3.1	Introduction	456
18.2.3.2	Immunotoxicogenomics	456

18.2.3.3	Interpretation of Results	457
18.2.3.4	Toxicogenomics for Prediction of Effects	457
18.2.3.5	Target Organs and Cells for Immunotoxicity	458
18.2.3.6	Conclusions	458
18.3	Summary	459
	References	459
19	<i>In Vitro</i> Phototoxicity Testing: a Procedure Involving Multiple Endpoints	471
	<i>Laurent Marrot and Jean-Roch Meunier</i>	
19.1	Introduction	471
19.2	Optical Considerations: Relevant UV Sources and Sunlight Absorption	472
19.2.1	Working with the Appropriate Artificial Sunlight Source Determines the Relevance of Phototoxicity Screening	472
19.2.2	When to Study the Phototoxicity of a Substance?	474
19.3	<i>In Silico</i> Methods for Prediction of Phototoxicity – (Q)SAR Models	474
19.3.1	Global Models	475
19.3.2	Local Models	475
19.4	Photoreactivity <i>In Tubo</i> : Prescreening of Compounds Producing ROS Upon Sunlight Exposure	478
19.4.1.	Biochemical Detection of Photoinduced ROS	478
19.4.2	Photo-Cleavage of Isolated Plasmid DNA	479
19.4.3	Photo Red Blood Cells Test	479
19.5	Microbiological Models for Photomutagenesis Assessment	480
19.5.1	Photo-Ames Test	480
19.5.2	The Yeast Model	480
19.6	Photocytotoxicity and Photogenotoxicity in Mammalian Cells: Regulatory Tests and Beyond	482
19.6.1	The 3T3 NRU Assay: a Validated Test for the Assessment of a Photoirritation Potential	482
19.6.2	Photogenotoxicity: an Endpoint Without Corresponding <i>In Vivo</i> Equivalents	483
19.7	Reconstructed Skin: a Model for Mimicking Phototoxicity in the Target Organ	486
19.8	Conclusions	488
	References	489
	Index	495

